These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16354901)

  • 1. Paget's disease and bisphosphonates.
    Liel Y
    N Engl J Med; 2005 Dec; 353(24):2616-8; author reply 2616-8. PubMed ID: 16354901
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacological treatment of osteitis deformans (Paget's bone disease)].
    Brixen KT; Abrahamsen B; Kassem MS; Mosekilde L
    Ugeskr Laeger; 2005 Feb; 167(9):1009-12. PubMed ID: 15803994
    [No Abstract]   [Full Text] [Related]  

  • 3. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
    [No Abstract]   [Full Text] [Related]  

  • 5. Paget's disease and bisphosphonates.
    Rendina D; De Filippo G; Mossetti G
    N Engl J Med; 2005 Dec; 353(24):2616-8; author reply 2616-8. PubMed ID: 16365936
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
    [No Abstract]   [Full Text] [Related]  

  • 8. [Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
    Bannwarth B
    Presse Med; 2002 Mar; 31(8):340-2. PubMed ID: 11913075
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Paget's disease and its therapeutic management].
    Orcel P; Rousière M
    Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
    Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
    Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chondrosarcoma in Paget's disease of bone.
    Ibáñez R; Gutierrez R; Fito C; del Val N; Loza E
    Clin Exp Rheumatol; 2005; 23(2):275. PubMed ID: 15895907
    [No Abstract]   [Full Text] [Related]  

  • 16. Risedronate for Paget's disease of bone.
    Med Lett Drugs Ther; 1998 Aug; 40(1034):87-8. PubMed ID: 9731243
    [No Abstract]   [Full Text] [Related]  

  • 17. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
    Drake WM; Kendler DL; Brown JP
    Clin Ther; 2001 Apr; 23(4):620-6. PubMed ID: 11354395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates.
    Lambrinoudaki I; Christodoulakos G; Botsis D
    Ann N Y Acad Sci; 2006 Dec; 1092():397-402. PubMed ID: 17308164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic effects of risedronate on Paget's disease of bone].
    Takata S
    Clin Calcium; 2006 Sep; 16(9):1508-12. PubMed ID: 16951476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.